Safety and Quality of Life Study of Aflibercept in Patients With Metastatic Colorectal Cancer Previously Treated With an Oxaliplatin-Based Regimen
Last updated on July 2021Recruitment
- Recruitment Status
- Completed
- Estimated Enrollment
- 900
Summary
- Conditions
- Colorectal Cancer Metastatic
- Type
- Interventional
- Phase
- Phase 3
- Design
- Allocation: N/AIntervention Model: Single Group AssignmentMasking: None (Open Label)Primary Purpose: Treatment
Participation Requirements
- Age
- Between 18 years and 125 years
- Gender
- Both males and females
Description
Each participants will be treated until disease progression, unacceptable toxicity, death, Investigator's decision or participant's refusal for further treatment (whichever comes first). Participants were followed-up during study treatment and for at least 30 days after last administration.
Each participants will be treated until disease progression, unacceptable toxicity, death, Investigator's decision or participant's refusal for further treatment (whichever comes first). Participants were followed-up during study treatment and for at least 30 days after last administration.
Tracking Information
- NCT #
- NCT01571284
- Collaborators
- Regeneron Pharmaceuticals
- Investigators
- Study Director: Clinical Sciences & Operations Sanofi
Get Well Soon